Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992
Annals of the Rheumatic Diseases 05 August 2020 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.
Annals of the Rheumatic Diseases, May 2020
Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.
Arthritis Care Res (Hoboken) 2020;72(8):1112-1121
Annals of the Rheumatic Diseases 2020;79:760-770
Annals of the Rheumatic Diseases 2020;79:778-786
Rheumatol Ther 2020 doi.org/10.1007/s40744-020-00209-4
RMD Open 2020;6:e001174 doi:10.1136/rmdopen-2020-001174